Vallabhajosula and colleagues performed the first studies using a [99mTc]Tc-tagged PSMA-i compound in healthy men and patients with metastatic PCa, to compare the biodistribution, pharmacokinetics, tumor uptake, and radiation dosimetry of two pioneering agents, the [99mTc]Tc-MIP-1404 and the [99mTc]Tc-MIP-1405 (see Table 3) [129]. This evidence concerns the gene FOLH1 and neoplasm.